The original case report on the entity describes a DEK::AFF2 carcinoma with an excellent response to immune checkpoint inhibitors (ICI)—anti-PD-L1—which is related to DEK::AFF2 neoantigen-specific T-cell response during tumor regression [4]. This evidence concerns the gene AFF2 and neoplasm.